Filter
412
Filtered Results: 412
Text search:
ECDC
(European
Centre
for
Disease
Prevention
and
Control)
Featured
Recommendations
39
New Publications
81
Language
Document type
No document type
176
Guidelines
77
Studies & Reports
71
Fact sheets
27
Manuals
19
Situation Updates
9
Strategic & Response Plan
9
Resource Platforms
6
Infographics
6
Training Material
4
Online Courses
4
Brochures
2
Videos
2
Countries / Regions
Western and Central Europe
78
Ukraine
18
Germany
17
Eastern Europe and Central Asia
16
Eastern Europe
16
Africa
7
Global
6
Guinea
5
Madagascar
5
West and Central Africa
5
Russia
5
Sierra Leone
4
Liberia
4
Latin America and the Carribbean
4
Mozambique
3
Brazil
3
Congo, Democratic Republic of
2
Guinea-Bissau
2
North Macedonia
2
Colombia
2
Myanmar / Burma
2
East and Southern Africa
2
Middle East and North Africa
2
Paraguay
2
Estonia
2
Romania
2
Spain
2
Burkina Faso
1
Nigeria
1
Senegal
1
Mali
1
Côte d’Ivoire / Ivory Coast
1
Cameroon
1
Niger
1
Haiti
1
South Sudan
1
Turkey
1
Rwanda
1
Benin
1
Angola
1
Western Pacific Region
1
Asia
1
Venezuela
1
Italy
1
Albania
1
Armenia
1
Congo-Brazzaville
1
Tajikistan
1
Bulgaria
1
Moldova
1
Uzbekistan
1
Georgia
1
Turkmenistan
1
Denmark
1
France
1
Portugal
1
Authors & Publishers
Publication Years
Category
Countries
76
Clinical Guidelines
19
Key Resources
19
Public Health
9
Capacity Building
3
Women & Child Health
2
Pharmacy & Technologies
1
Toolboxes
COVID-19
84
Rapid Response
55
AMR
55
HIV
54
TB
42
Zika
25
Ebola
24
Refugee
21
Conflict
17
Planetary Health
11
Mental Health
5
Global Health Education
4
Specific Hazards
3
Cholera
2
Caregiver
2
NTDs
2
Polio
1
Natural Hazards
1
Pharmacy
1
18 Janaury 2021
EU/EEA Member States and the UK have increased their laboratory capacity tremendously over the past 11 months as the majority of the Member States reported sufficient testing capacity until March 2021.
Many countries are ad...
This report provides an overview of the main findings of the 2019–2020 harmonised AMR monitoring in the main food-producing animal populations monitored, in carcase/meat samples and in humans. Where available, monitoring data obtained from pigs, c...
The update of the ESTC was conducted as a joint endeavour with ERS, consulting experts from international societies and organisations, national TB programmes, civil society and affected communities....
The checklist tool described in this handbook is intended for EU/EEA public health authorities who need to assess the capacity for communicable disease...
Options for the decontamination and reuse of respirators in the context of the COVID-19 pandemic
recommended
Guiding principles for reuse are:
Respirators which have been visibly contaminated (e.g. during procedure at intubated patients, such as suction cleaning of airways, taking probes, extubation attempts, etc.) or are damaged or not fitting, shoul...
This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in
Rwanda for the European Union/... Economic Area (EU/EEA). MVD is a severe disease in humans and,
although uncommon, it has the potential to cause epidemics with significant case fatality. All recorded MVD
outbreaks to date have originated in Africa. MVD is not an airborne disease and is considered not to be
contagious before symptoms appear. Direct contact with the blood and other body fluids of infected people
and animals or indirect contact with contaminated surfaces and materials like clothing, bedding and medical
equipment is required for transmission. The risk of infection is minimised when proper infection prevention and
control precautions are strictly followed. There is no approved treatment or vaccine for MVD; however, several
pharmaceuticals and candidate MVD vaccines are under investigation.
This document aims to provide guidance to EU/EEA public health authorities, public health professionals and healthcare practitioners for the management of persons having had contact with cases of Eb...
Marburg virus disease (MVD), formerly known as Marburg haemorrhagic fever, is a severe disease in humans caused by Marburg marburgvirus (MARV). Although MVD is uncommon, MARV has the potential to ca...
The second ECDC/EFSA/EMA joint report on the integrated analysis of antimicrobial consumption (AMC) and antimicrobial resistance (AMR) in bacteria from humans ... food-producing animals addressed data obtained by the Agencies’ EU-wide surveillance networks for 2013–2015. AMC in both sectors, expressed in mg/kg of estimated biomass, were compared at country and European level. Substantial variations between countries were observed in both sectors. Estimated data on AMC for pigs and poultry were used for the first time. Univariate and multivariate analyses were applied to study associations between AMC and AMR. In 2014, the average AMC was higher in animals (152 mg/kg) than in humans (124 mg/kg), but the opposite applied to the median AMC (67 and 118 mg/kg, respectively). In 18 of 28 countries, AMC was lower in animals than in humans. Univariate analysis showed statistically-significant (p < 0.05) associations between AMC and AMR for fluoroquinolones and Escherichia coli in both sectors, for 3rd- and 4th-generation cephalosporins and E. coli in humans, and tetracyclines and polymyxins and E. coli in animals. In humans, there was a statistically-significant association between AMC and AMR for carbapenems and polymyxins in Klebsiella pneumoniae. Consumption of macrolides in animals was significantly associated with macrolide resistance in Campylobacter coli in animals and humans. Multivariate analyses provided a unique approach to assess the contributions of AMC in humans and animals and AMR in bacteria from animals to AMR in bacteria from humans. Multivariate analyses demonstrated that 3rd- and 4th-generation cephalosporin and fluoroquinolone resistance in E. coli from humans was associated with corresponding AMC in humans, whereas resistance to fluoroquinolones in Salmonella spp. and Campylobacter spp. from humans was related to consumption of fluoroquinolones in animals. These results suggest that from a ‘One-health’ perspective, there is potential in both sectors to further develop prudent use of antimicrobials and thereby reduce AMR.
This report presents the main characteristics of Ebola emergency preparedness in three EU Member States. Findings are organised in five sections: preparedness planning, organisational structures, recourses and capacities, intersectoral ... cross-border collaboration, and country-specific findings
ECDC MISSION REPORT 19–21 September 2016 ; 14–15 November 2016
The aim of this document is to support public health preparedness planning with regard to personal protective equipment (PPE) needs in healthcare settings where patients suspected or confirmed to have been infected with the novel coronavirus 2019-nCoV are being treated.
This document provides guidance to EU/EEA Member States on environmental cleaning in healthcare and non-healthcare settings during the COVID-19 pandemic.
Free and open access application that gives you direct access to key updates and reports on communicable disease threats of concern to the EU on yo...
Accessed 6 March 2019.
